The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose three times daily for treatment of community-acquired pneumonia suspected to be due to Streptococcus pneumoniae. Success of treatment was determined by a combination of clinical assessment and chest radiography. Pneumococcal pneumonia was the confirmed diagnosis for 177 patients (54%). Overall rates of success among evaluable patients were equivalent between drugs, both at the end of treatment (sparfloxacin, 92%; amoxicillin, 87%) and at follow-up (sparfloxacin, 89%; amoxicillin, 84%). Sparfloxacin was well-tolerated and produced fewer gastrointestinal effects than amoxicillin. In conclusion, sparfloxacin is a safe and effective alternative to high-dose amoxicillin for the treatment of suspected pneumococcal community-acquired pneumonia.
Despite progress in diagnostic techniques and treatments, Although several guidelines are available to the practicing the management of pneumonia is still a challenge to physicians.
physician for a rational approach to the initial management The disease remains one of the leading causes of morbidity of CAP [15] , these cannot encompass all eventualities. Since and mortality and is a common cause of hospitalization of resistance of many respiratory pathogens is now widespread, adults, placing a heavy burden on health services [1 -5] . The choosing a drug for empirical use is difficult. It is essential precise etiology is uncertain in a substantial number of cases that the agent have good activity against S. pneumoniae, since [2, 5, 6] , even when a range of diagnostic techniques are used, this is the major pathogen to be covered, but activity is required and because of the potential severity of the disease, empirical against the other respiratory organisms, particularly since infectreatment has to be initiated promptly [7] . Even if attempts are tions can be polymicrobial. made to identify the etiologic agent, there is normally at least Sparfloxacin has good activity against S. pneumoniae, both a 48-hour delay in obtaining results of cultures of bronchopulin vivo and in vitro [16] , regardless of whether the strain is monary samples. Indeed, bacteriologic studies usually require resistant to penicillin, tetracycline, or erythromycin. In addispecialized or invasive techniques.
tion, sparfloxacin is active against other pathogens common in The predominant pathogen is Streptococcus pneumoniae respiratory tract infections, such as Haemophilus influenzae, [6, 8 -10] , traditionally highly susceptible to penicillin, but M. pneumoniae, Chlamydia pneumoniae, Moraxella catarrhstrains with reduced susceptibility to penicillin and other antibialis, Staphylococcus aureus, and L. pneumophila [17] . otics, including macrolides and tetracyclines, are now found Several features of the pharmacokinetics of sparfloxacin worldwide [11, 12] . Previously unrecognized agents such as make it well suited for use in respiratory tract infections [18] .
Legionella pneumophila, Mycoplasma pneumoniae, and Chla-
The compound is well-absorbed from the gastrointestinal tract mydia species have been implicated increasingly as causes of and is excreted with a half-life of Ç20 hours, allowing for community-acquired pneumonia (CAP) [6, 8, 9, 13, 14] . These once-daily dosing. It also penetrates the respiratory tract particorganisms are not susceptible to b-lactam antibiotics, and their ularly well, producing levels in the tissues that exceed the susceptibility to macrolides and tetracyclines varies. plasma levels considerably [19] . The 200-mg daily dose of sparfloxacin, following a 400-mg loading dose on day 1, proSee the editorial response by Young on pages 1322 -3.
duces a steady state after the second dose, with a peak serum concentration of 1.4 mg/L and a trough concentration of Ç0.5 mg/L [18] . The purpose of this clinical trial was to determine the clinical value of sparfloxacin as a first-line treatment for adults needing France and Spain as first-line empirical therapy for CAP sus-(creatinine level of ú200 mmol/L) or with a WBC count of õ4,000/mL or ú30,000/mL, and pregnant or lactating women pected to be caused by S. pneumoniae.
were also excluded. Patients concomitantly taking antacids (H 2 antagonists were permitted), systemic corticosteroids (ú30 Materials and Methods mg/d), allopurinol, or iron salts were not included. It was permissible for patients to have received antibiotic treatment for This was a multicenter, randomized, double-blind trial comparing the efficacy and safety of once-daily sparfloxacin and the present pneumonia prior to study enrollment, but such treatment must have lasted for õ24 hours. a 1-g t.i.d. dosage of amoxicillin. This study was conducted from October 1991 to October 1992 at 46 centers in France, 5 in South Africa, and 4 in Switzerland. The protocol was Monitoring approved by ethics committees according to the local requirements. Written consent was obtained from all patients, and the A complete physical examination, chest radiography, urinary analysis, and blood sampling for arterial blood gas levels and study was conducted in accordance with the Declaration of Helsinki (Hong Kong amendment).
for hematologic and biological analysis were performed at the pretreatment visit (visit 1). On study days 2 -4, a clinical examiStudy drugs were administered orally by the double-dummy technique: each patient received two capsules three times daily, nation and, if necessary, chest radiography were repeated in order to assess the early effect of treatment (visit 2). The endwith each capsule containing sparfloxacin (200 mg), amoxicillin (500 mg), or placebo. All capsules were identical in appearof-treatment assessment (visit 3) occurred between days 14 and 21, and a complete physical examination, chest radiography, ance. The sparfloxacin regimen consisted of 400 mg on day 1 followed by 200 mg once daily, with a placebo capsule at 7 respiratory sampling (if necessary), blood sampling for hematologic and biochemical analysis, and urinary analysis were per-A.M. and two placebo capsules at 3 P.M. and 11 P.M. Amoxicillin (1,000 mg three times daily) was given as two 500-mg capsules formed. The follow-up assessment (visit 4) was performed between days 39 and 41 and consisted of a physical examination; at 7 A.M., 3 P.M., and 11 P.M. A treatment duration of 10 days was recommended, although this could be extended to 14 days chest radiography if findings were not normal at the previous visit; respiratory sampling for culture in cases of relapse; and at the discretion of the physician.
hematologic, biochemical, and urinary analysis in any cases with abnormalities evident at visit 3.
Study Subjects
If the clinical response seemed unduly slow, physicians were allowed to withdraw patients from the study and to administer The study population consisted of adult patients at least 18 years of age who were hospitalized for a presumed diagnosis of the drug of their choice, but the code was not broken at this time. pneumococcal CAP. Pneumonia was defined by the following criteria: fever (temperature of ú38ЊC), a new alveolar infiltrate evident on a chest radiograph (involving no more than one Microbial Analyses lobe on each side if bilateral), and at least one sign or symptom (cough, dyspnea, chills, and purulent sputum production). A Before treatment was started, three blood cultures were mandatory. Bronchopulmonary secretions were collected for micropresumptive diagnosis of pneumococcal pneumonia was made if at least two of the following five signs or symptoms were bial culture by protected distal brushing, bronchial aspiration during fiberoptic bronchoscopy, transtracheal puncture, sputum present: sudden onset, fever (temperature of ú39ЊC) with chills, chest pain, localized alveolar consolidation evident on collection, or sampling of pleural fluid, if available. A bacterial count of 2,103 in specimens from protected distal brushing, a chest radiograph, and the exclusive or predominant presence of gram-positive cocci with the appearance of S. pneumoniae transtracheal aspiration, and fiberoptic protected distal aspiration was considered significant. For sputum and bronchial aspiin a smear of a respiratory sample.
Patients were not included if they were known to be allergic ration specimens, only those containing õ10 squamous epithelial cells and ú25 leukocytes were considered acceptable for to quinolones or penicillins. They were excluded if they presented with a severe infection requiring parenteral antibiotic culture and susceptibility testing. In these specimens, colony counts of at least 10 6 cfu/mL (for S. pneumoniae) or 10 7 cfu/ therapy (adult respiratory distress syndrome, septic shock, need of mechanical ventilation, or concomitant meningitis); a severe mL (for other organisms) were required for the organism to be regarded as the cause of the pneumonia. concomitant disorder likely to interfere with the clinical course of pneumonia; AIDS (although HIV-positive patients could be Respiratory samples were obtained again if the treatment was considered a failure at the end of the drug-administration included); a drug abuse habit; severe neuropsychiatric disease; or hepatic disease (with an aspartate aminotransferase [AST] period or at the follow-up visit (see below). Blood samples for serological testing were obtained at inclusion and 15 days later or alanine aminotransferase [ALT] level ú3 1 the upper limit of normal or total bilirubin level ú1.5 1 the upper limit of if no pathogen had been isolated at inclusion. Serum and urine samples were also obtained at inclusion and were frozen for normal). Cirrhotic patients, those with chronic renal failure subsequent detection of pneumococcal antigen by countercurAll cases in which therapy was discontinued on day 3 or day 4 because of evident clinical and/or radiological worsening rent immunoelectrophoresis.
Pneumococcal capsular antigen detection was performed by of the pneumonia were considered early failures. Overall success was determined on the basis of these assesscountercurrent immunoelectrophoresis according to the method described by El Refaie and Dulake [20] . The search for IgG ments combined and was defined (1) [22] ; and for overall failures. Those patients with conflicting radiological or clinical data on visit 3 were classified according to the outcome antibodies to Chlamydia group antigen by CF, according to Bradstreet and Taylor [23] . The documentation of infection on visit 4; those with conflicting or missing data on visit 4 were classified by the steering committee after individual and with atypical pathogens required a 4-fold increase in the titer of any serological value (at least to §64 for Pneumophila blind review. serogroup 1 antigen).
The disk diffusion method was employed to assess bacterial
Bacteriologic Response
susceptibility to sparfloxacin and ampicillin in each microbiology center. Confirmation of S. pneumoniae -positive cultures The bacteriologic response was defined as eradication when and determination of susceptibility with use of a microdilution the initial pathogen was absent after treatment or at follow-up method were done by two central laboratories: National Referor when sample collection was no longer possible because the ence Centre for Streptococcus pneumoniae (Dr. Geslin), Centre patient's productive cough had disappeared. It was defined as Hospitalier Intercommunal, Créteil, France; and Lancet Labopersistence or colonization when the initial pathogen remained ratories (Dr. Miller), Johannesburg, South Africa. The susceptiafter treatment in association with an overall failure or an bilities of all isolated strains to sparfloxacin, amoxicillin, penioverall success, respectively. A relapse was defined by absence cillin G, ciprofloxacin, and erythromycin were determined. The of the initial pathogen in the posttreatment sample, followed susceptibility of S. pneumoniae strains to oxacillin was also by its isolation again at follow-up. assessed with a 5-mg oxacillin disk in order to detect penicillin resistance.
Safety Analysis

Clinical Response
Safety was determined on the basis of clinical evaluation, urinalysis, hematology, and biochemistry at each visit after the Efficacy analyses were performed on both the intent-to-treat start of therapy. All adverse experiences revealed by nonspepopulation and the evaluable population at two intervals: from cific questioning or reported voluntarily by the patients were study enrollment (visit 1) to end of treatment (visit 3) and from noted at each visit. The investigator classified the severity of study enrollment (visit 1) to follow-up (visit 4). An overallthese as mild, moderate, or severe/life threatening and classified efficacy classification was used that combined both clinical and their relationship to the study medication as unrelated, possibly radiological changes and was expressed simply as ''success'' related, or probably related. The international COSTART clasor ''failure.'' This classification was determined by the applicasification was used to classify the individually described adtion of predefined criteria. An external steering committee reverse events. viewed the patients' records when the data were contradictory. This approach has been described previously [24] .
Clinical effects were classified as cure, improvement, or fail-
Statistical Analysis
ure with use of the predetermined criteria. Clinical cure included the absence of fever (temperature of õ37.5ЊC), chills, Statistical analyses were performed to determine overall efficacy at the end-of-treatment and follow-up visits for both the chest pains, cough, or dyspnea and the absence of sputum production at the follow-up visit. However, patients with carintent-to-treat study population and the evaluable patients. The intent-to-treat population was defined as all patients who rediac failure, concomitant bronchopulmonary disease, persistent cough or dyspnea, or nonpurulent sputum could still be classiceived at least one dose of the study drug. The criteria for evaluability were as follows: a pulmonary infiltrate revealed fied as clinically cured, provided the symptoms were no worse than at admission. Clinical improvement was classified as the by chest radiography performed at admission; clinical diagnosis of pneumonia; fever (temperature of §38ЊC); no associated absence of chills and fever, but other symptoms such as chest pain, cough, or sputum production could still be present. All pathology such as pulmonary embolism, bronchial cancer, acute pulmonary edema, or myocardial infarction; at least 2 other cases were classified as failures. Radiological changes were classified directly by the investigators as worse, no days of therapy if the outcome was failure, and 5 days otherwise; no antibiotic received within 24 hours before the first change, improvement, or resolution. The two treatment groups were compared by means of a received amoxicillin were significantly heavier than those who were treated with sparfloxacin (P Å .04). Otherwise, the two one-sided equivalence approach. The objective was to demonstrate that the success rate with amoxicillin was not more than groups were similar in terms of tobacco and alcohol consumption, but more patients in the sparfloxacin group than in the 10% greater than that with sparfloxacin. A two-sided 90% confidence interval of the difference in these success rates was amoxicillin group had a chronic bronchopulmonary disease (difference not statistically significant; P Å .11), and slightly computed to control for a type I error of 5%. Sample size was based on the assumption of a success rate of 85% for amoxicilmore amoxicillin patients were alcoholics (difference not statistically significant; P Å .13). Sputum production was also lin, with 158 patients per group in order to obtain an 80% probability of including equivalence if both success rates were slightly more frequent in the sparfloxacin group (83% vs. 74%), and bilateral pneumonia was slightly more frequent in the truly equal and a 95% probability of respecting equivalence if amoxicillin was truly superior to sparfloxacin by a 10% greater amoxicillin group (9%) than in the sparfloxacin group (6%). Six patients (one in the sparfloxacin group and 5 in the success rate. All statistical analyses were carried out with the SAS software package (SAS Institute, Cary, NC 
Efficacy
The average duration of treatment was 10.8 days. Both drugs cillin recipients (20.6%). The overall rate of documented pneumococcal pneumonia in this trial was therefore 53.8% (177 were very effective in the intent-to-treat and evaluable populations at both endpoints (end of treatment and follow-up) (table patients), with a slightly higher rate in the sparfloxacin group (61.6%) than in the amoxicillin group (46.5%). S. pneumoniae 6). Sparfloxacin was at least as effective as high-dose amoxicil- The efficacy results among patients with the usual risk factors for treatment failure (elderly age; positive blood cultures; respiratory rate, ú30/min; diastolic blood pressure, õ60 mm Hg; partial pressure of arterial oxygen [PaO 2 ], õ60 mm Hg; lin; the success rates for sparfloxacin were 91.9% at the end of treatment and 88.9% at follow-up, compared with 87.3% and bilateral pneumonia; and pleural effusion) at the time of inclusion are detailed in table 8. Bilateral pneumonia and positive 84.3% for amoxycillin. However, discontinuation of the study drug on day 3, 4, or 5 because of poor response (early failure) blood cultures were associated with a slightly lower cure rate for both compounds, and an age ú65 years, pleural effusion, occurred more often in the amoxicillin group (11 patients) than in the sparfloxacin group (three patients) (table 6). Apyrexia was and low PaO 2 value also were associated with a somewhat higher failure rate in the amoxicillin group. achieved by day 4 in 74.5% of patients who received sparfloxacin and in 67.2% of those receiving amoxicillin.
The total number of failures related to ineffective antibiotic therapy (not including cases considered failures because the The efficacy rates in cases of documented pneumococcal pneumonia were also high (89% -93%) and similar in the two patients were lost to follow-up at visit 3 or 4 or because of the occurrence of an intercurrent event or associated pathology) groups, both at the end of treatment (visit 3) and at follow-up (visit 4) (table 7). The success rate among patients whose blood was 14 in the sparfloxacin group, in contrast with 22 in the amoxicillin group. S. pneumoniae was the causative agent in cultures were positive for S. pneumoniae was 20 of 24 receiving sparfloxacin and 15 of 17 treated with amoxicillin. A sparfloxsix of the amoxicillin recipients whose therapy failed and in eight of the sparfloxacin-failure cases. A high proportion of acin-group patient whose protected-brush bronchoscopy isolate was thought to be pathogenic and had decreased susceptibility the amoxicillin-therapy failures (11 of 22) occurred in the first 5 days. The two evaluable amoxicillin recipients with pneumoto penicillin (MICs: 1 mg/L for penicillin and 0.25 mg/L for sparfloxacin) was treated successfully with sparfloxacin; two coccal pneumonia caused by a strain with moderate resistance to penicillin (MIC 90 , 0.5 mg/L) were cured, as was the patient patients whose isolates were recovered under the same conditions (MICs: 0.5 mg/L for penicillin; 0.125 mg/L and 0.50 who received sparfloxacin (MIC 90 of penicillin, 1.0 mg/L). There were no cases of bacteriologically documented failure mg/L, respectively, for sparfloxacin) were included in the amoxicillin group and were treated successfully with a dosage in the sparfloxacin group. In the amoxicillin group there were three cases of persistence, one at the end of treatment (due to of 3 g/d.
Of the H. influenzae infections, 10 of 11 treated by sparflox-S. aureus) and two at follow-up (due to S. pneumoniae and a gram-negative Enterobacteriaceae organism). There was also acin and all 7 treated by amoxicillin were cured (table 7). The 1 patient with an M. catarrhalis infection in the sparfloxacin one case of colonization with an Enterobacteriaceae organism in the amoxicillin group. group was cured, as were 2 of 3 patients in the amoxicillin to the study drug treatment.
Early failure 3 (2.4) 11 (7.9) Patterns of change in laboratory values and, in particular, AST, ALT, creatinine, hemoglobin, and platelet values, were similar in the two treatment groups.
Safety Analysis
Gastrointestinal disturbances were more common in the Discussion amoxycillin group (19 events) than in the sparfloxacin group (10 events) (table 9). Nine amoxicillin-treated patients comIn this study of acute presumed pneumococcal CAP in adults requiring hospitalization, once-daily oral dosing with 200 mg plained of abdominal pain, but only one sparfloxacin recipient did. Diarrhea was reported by 6 patients who received sparof the new fluoroquinolone sparfloxacin was as effective in terms of overall efficacy as a high dose (3 gm daily) of amoxifloxacin and 4 who received amoxicillin, vomiting by 3 and 6, respectively, and rashes by 2 and 6, respectively.
cillin. Overall tolerance of both drugs was good, although there was a higher incidence of gastrointestinal disturbances in the Although the instructions to patients clearly recommended that they avoid sun exposure during the duration of treatment amoxicillin group than in the sparfloxacin group. Rashes were reported by 6 patients receiving amoxicillin and 2 receiving and the three following days, phototoxicity was reported by three sparfloxacin recipients. All three recovered spontanesparfloxacin, and 3 recipients of sparfloxacin had a phototoxic response despite recommendations to avoid sun exposure. ously. In two patients, the phototoxicity was associated with exposure to sun on day 11 or 14 of the study. One of these
The frequency of well-documented pneumococcal pneumonia was high in this study, and both drugs were shown to be very patients had mild erythema of the face, and the other had moderate erythema of the face and hands. The third patient effective in this population of patients, with an 89% success rate in the sparfloxacin group and a 91% rate in the amoxicillin developed a mild and very transitory facial response 33 days after the end of treatment. There were an additional five reports group at the end of treatment. The MIC 90 of sparfloxacin against S. pneumoniae was 0.25 of insomnia and depression in the sparfloxacin group and two of confusion in the amoxicillin group. mg/L, a figure in close agreement with those in the literature [8, 9, 13, 14] . Nevertheless, S. pneumoniae would appear to be the predominant bacterial the number of resistant organisms has increased sharply in pathogen [2, 7, 9, 10] and should therefore be systematically some areas such as southern Europe. Although newer macrocovered by any drug used empirically.
lides such as fluoroquinolones penetrate tissues very well, they The increasing prevalence of reduced susceptibility to peniare ineffective against erythromycin-resistant strains. Morecillins among S. pneumoniae isolates and the growth of over, erythromycin resistance is often associated with penicillin b-lactamase production in strains of H. influenzae and M. caresistance. tarrhalis [12] have reduced the value of conventional penicilCiprofloxacin has been used in the treatment of various respilins. One approach to therapy for CAP has been to use ratory tract infections, but the compound has poor activity b-lactamase-stable compounds such as third-generation cephaagainst pneumococci [16] , as was demonstrated in this study. losporins or b-lactamase-inhibitor combinations such as coThis has been reflected in the poor clinical response seen in amoxiclav. However, these compounds still lack full activity some cases of pneumococcal pneumonia, and the use of ciagainst strains of pneumococci with decreased susceptibility profloxacin for respiratory tract infections due to pneumococci or resistance to penicillin [26] . An alternative approach has has been criticized by Freiden and Mangi [28] and Cruciani been to use high-dose amoxicillin or ampicillin [27] , since it and Bassetti [29] . is claimed that high doses provide levels in vivo that are inhibi-
In conclusion, this study demonstrated that sparfloxacin, tory for S. pneumoniae. On the other hand, the insusceptibility given in a single daily dose for 10 days, was as effective as a of many of the atypical pathogens to b-lactams could be a high dose of amoxicillin given 3 times daily for the treatment disadvantage for these drugs if they are used as empirical of acute CAP in hospitalized patients, of whom a significant therapy.
proportion had confirmed pneumococcal pneumonia. SparThe value of the macrolide erythromycin, used frequently floxacin was well tolerated, producing fewer gastrointestinal as empirical therapy for CAP in patients with known allergy effects than amoxicillin. Three mild-to-moderate phototoxic to penicillin or when penicillin-resistant pneumococci are the reactions were seen in the sparfloxacin group, thus emphasizing suspected pathogens, has been eroded, since, as noted above, the precautions concerning use of the drug. No one cardiovascular event was related to electrocardiographic abnormalities caused by sparfloxacin. The good activity of sparfloxacin against pneumococci, infactors at inclusion.
cluding penicillin-resistant strains, combined with its broad spectrum of bactericidal activity against other pathogens impliNo. of recipients cured/ no. in group cated in CAP, its excellent tissue penetration, and the fact that it can be given in a single daily dose, makes it a good choice
